Diagnosing Cancer

Through Tumor Related Microbial Biomarkers

Micronoma liquid biopsy technology interrogates the microbial signal to detect and predict cancer with clinical-grade accuracy.


Our Focus

Saving patient lives with a minimally-invasive, cancer screening test.

Latest News

Micronoma Appoints Magda Marquet Chairman of the Board

Biotech maven joins early-stage cancer detection company utilizing innovative microbiome analysis SAN DIEGO, Sept. 30, 2020 /PRNewswire/ -- Micronoma, an early stage cancer-detection start-up seeking to develop and commercialize a minimally-invasive, unique...

Micronoma Launches with $3 Million Seed Funding

For Immediate Release Media Contact: Celia Sepulveda, Celia.Sepulveda@Micronoma.com, 858.337.1326   Micronoma Launches with $3 Million Seed Funding   First early cancer-detection company to use microbial biomarkers in diagnostics   San Diego, Calif....

Humans and Microbes

Humans and microbes co-exist in a mutual beneficial relationship in our bodies. Microbes can be found naturally not only in our stools, but also in our mouths, tissues and even our blood.

The Microbiome

The microbiome is the community of all the microbes—bacteria, fungi, protozoa and viruses—that live on and inside the human body.

Microbes and Cancer

Microbes are now known to be found in human tissues, including cancer tissues. Micronoma is going a step further and looking at microbial signatures that would be predictive of a tumor in circulating blood.

Micronoma can detect and distinguish microbes in blood and predict if a patient is cancer free or presenting a specific cancer type.

Minimally-invasive blood
draw to collect samples
for testing.

Pioneering microbiome
research, discovery, and

Using genomic sequencing to
accurately distinguish
microbial signatures.

Using computational
pipelines to decipher and
interpret data.



New cancer cases
worldwide each year


Cancer deaths each year,
most preventable with
early detection


Global liquid biopsy market
forecast for 2023*

*BCC Research

 Better Approach to Liquid Biopsy

A liquid biopsy is a test done on a sample of blood to look for circulating tumor cells (CTC) or DNA that is shed from the tumor. Liquid biopsies may help find cancer at an early stage.


However, CTCs and ctDNA are scarce, fragile, and heterogenous, which means they are difficult to detect and may be missed. Additionally, they may not be cancer-specific, as various cancers can share many types of alterations.


Traditional liquid biopsies focus on all tumor DNA in the blood to identify the small mutation markers linked to the cancer. Present at often less than 0.1%, ensuring the capture of these rare biomarkers is a difficult task. At Micronoma, we focus on the microbial DNA. With noise and complexity removed, established microbial signatures are enriched and more evident.


OncobiotaTM is an approach to identify cancer tissue associated microbes and distinguish the presence and type of cancer.


Dr. Sandrine Miller
Montgomery Pharm. D. PhD

Founder, Board Member, President and CEO

Greg Poore

Founder,  Board Member, Chief Analytic Officer, Oncobiota™ Inventor

Rob Knight, PhD

Founder and Advisory Board, Oncobiota™ Inventor

Magda Marquet PhD

Chairman of the Board, Micronoma; Co-Founder, Ajinomoto Althea & AltheaDx and former Chairman of the Board of Directors of UCSD Moores Cancer Center


Wilson Sonsini
Goodrich & Rosati

Amy Duncan

San Diego Angel Conference (SDAC)
Goldfish Consulting

6432 Ferris Square
San Diego, CA 92121

Contact Us

If you have questions or would like to learn more, please email us at info@micronoma.com or contact us at media.relations@micronoma.com,